Search
Results
pagePrivacy Policy
Who we are Suggested text: Our website address is: https://backend.tricals.org. Comments Suggested text: When visitors leave comments on the site we collect the data shown in the comments form, and also the visitor’s IP address and browser user agent string to help spam detection. An anonymized string created ...
For patients
TRICALS aims to open clinical trials to all people with ALS!
trialsDAZALS
In this study, an investigational oral drug named dazucorilant (also called CORT113176) is being studied in people living with ALS.
pageSpecialists Overview
specialistsLeonard van den Berg
Professor of neurology, Neurologist and Chairman of TRICALS
specialistsMichael van Es
Neurologist & head of NMD department at UMC Utrecht
pageCentres
The TRICALS consortium consists of over 60 top ALS research centres across Europe.
They all work together on one common goal: finding a cure for ALS.
pageNews
Stay informed about the latest developments and achievements from TRICALS.
newsAmylyx withdraws RELYVRIO/AMX0035 from U.S. and Canadian markets
Yesterday, the pharmaceutical company Amylyx announced that they are withdrawing the drug AMX0035/Relyvrio/Albrioza from the market in the U.S. and Canada. This decision was based on the disappointing results from the PHOENIX-study, which were recently announced.